Malaria diagnosis is becoming an increasingly important part of global infectious disease management as healthcare systems focus on identifying infections earlier and improving treatment accuracy. Caused by Plasmodium parasites, malaria requires timely confirmation because symptoms such as fever, chills, headache and fatigue can overlap with several other infectious diseases. Conventional microscopy and rapid diagnostic tests (RDTs) remain central to clinical screening, particularly in countries where access to advanced laboratory facilities is limited.
-
According to the World Health Organization (WHO), approximately 282 million malaria cases and 610,000 deaths were estimated worldwide in 2024. This continuing disease burden reinforces the importance of accessible diagnostic technologies across hospitals, community health centres and remote healthcare facilities.
Beyond Conventional Testing: The Move towards Multi-Antigen Detection
-
One of the most important developments in malaria diagnostics is the growing need to identify parasites that conventional antigen-based tests may miss. Many commonly deployed RDTs detect the Plasmodium falciparum histidine-rich protein 2 (HRP2) antigen.
-
However, certain parasite strains have developed pfhrp2 and pfhrp3 gene deletions, affecting the reliability of these tests and potentially producing false-negative results. A 2025 study published in Nature Medicine reported that such deletions had been identified in 40 of 47 surveyed countries.
-
This development is encouraging diagnostic manufacturers and public health programmes to investigate alternative antigen targets, including Plasmodium lactate dehydrogenase (pLDH), and improve the reliability of combination-based testing systems.
WHO's 2026 Diagnostic Milestone: Three New Rapid Tests Enter the Spotlight
The diagnostic landscape received an important development in April 2026 when WHO prequalified three new malaria rapid diagnostic tests designed to address the limitations of HRP2-based detection. These tests target pLDH, providing an alternative for settings where HRP2 gene deletions are affecting diagnostic performance.
WHO recommends switching to alternative RDTs when more than 5% of falciparum cases are missed because of pfhrp2 deletions. In some affected areas of the Horn of Africa, missed diagnoses have reached as high as 80%. This development creates a significant opportunity for manufacturers developing improved antigen-detection technologies, particularly products designed for field use, national procurement programmes and high-burden healthcare environments.
Microscopy and Molecular Platforms: Different Technologies for Different Clinical Needs
-
Although rapid testing is expanding, microscopy continues to play an essential role in malaria diagnosis. Examination of thick and thin blood films enables laboratory professionals to identify Plasmodium species, observe parasite stages and estimate parasite density.
-
These capabilities are particularly important when monitoring severe infections and evaluating treatment responses.
-
Meanwhile, polymerase chain reaction (PCR) and other nucleic acid amplification technologies offer greater sensitivity for identifying low-density infections and distinguishing parasite species.
-
However, molecular testing generally requires more specialised laboratory infrastructure and is not recommended by WHO as a routine replacement for microscopy or RDTs in ordinary clinical case management.
-
The combination of rapid screening, microscopy confirmation and specialised molecular investigation therefore remains relevant across different healthcare settings.
You Can Go Through Our Latest Updated Insights Here: https://www.24lifesciences.com/malaria-diagnostics-market-9428
India's Malaria Elimination Programme Is Expanding the Testing Network
India provides an important example of how diagnostic accessibility supports national malaria elimination strategies. The country recorded approximately 255,500 malaria cases in 2024, compared with 227,564 cases in 2023, according to government surveillance data. India's National Centre for Vector Borne Diseases Control continues to strengthen early case detection through microscopy, antigen-based RDTs and community-level surveillance.
Its September 2025 surveillance advisory highlighted the involvement of ASHA workers, auxiliary nurse midwives and multipurpose health workers in identifying suspected infections. The national strategy also aims to achieve malaria elimination by 2030. These initiatives underline the importance of portable testing kits, reliable diagnostic supplies and trained healthcare personnel, particularly in tribal, hilly and geographically inaccessible communities.
The Unseen Demand: Testing in Pharmacies and Community Healthcare Facilities
Malaria diagnosis is not limited to large hospitals and government laboratories. Pharmacies, private medical retailers, primary healthcare centres and community clinics also influence how quickly patients receive testing and treatment. WHO's 2025 World Malaria Report highlighted that, across surveyed sub-Saharan African countries, only 43% of patients who obtained antimalarial medicines from private-sector providers reported having undergone a malaria test.
-
This indicates an important gap between medicine availability and confirmed diagnosis.
-
Improving access to affordable RDTs, strengthening private-sector testing practices and ensuring consistent product quality could help healthcare programmes reduce presumptive treatment and improve patient management.
Diagnostic Quality Assurance Becomes Central to Malaria Elimination
As testing volumes increase, diagnostic quality assurance is becoming just as important as product availability. Incorrect sample handling, inadequate storage conditions, poorly trained technicians and inconsistent interpretation can affect diagnostic outcomes. WHO's prequalification framework evaluates in-vitro diagnostic products through performance assessment, technical documentation and manufacturing inspections.
Its microscopy quality-assurance initiatives also support competency development among laboratory professionals across malaria-endemic countries. For diagnostic manufacturers, maintaining consistent sensitivity, specificity, shelf life and performance under different temperature conditions is essential for supplying products to diverse healthcare environments.
